Rituximab

CHEMBL1201576 Phase 4 Aprobado Antibody
Half-Life
22 days
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A monoclonal antibody that targets the CD20 protein on B cells, used to treat various B-cell lymphomas, leukemias, and autoimmune conditions like rheumatoid arthritis. It depletes CD20-positive B cells through multiple immune mechanisms, including antibody-dependent cellular cytotoxicity.

Áreas terapéuticas

Clases de fármacos

Mecanismo de acción

Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics (PK)

Half-Life 22 days

Pharmacodynamics (PD)

Mecanismo

Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A monoclonal antibody that targets the CD20 protein on B cells, used to treat various B-cell lymphomas, leukemias, and autoimmune conditions like rheumatoid arthritis. It depletes CD20-positive B cells through multiple immune mechanisms, including antibody-dependent cellular cytotoxicity.

Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Key pharmacokinetic parameters for Rituximab: Half-life: 22 days.

Yes, Rituximab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201576. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.